权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeted Biomarker Panels and Pre-processing Device for the Rapid Assessment of Radiation Injury in Easily Accessible Biofluids

用于快速评估易于获取的生物流体中的辐射损伤的靶向生物标记物组和预处理装置

基本信息

批准号：
10724654
负责人：
Evagelia Christos Laiakis
金额：
$ 16.5万
依托单位：
GEORGETOWN UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-27 至 2026-04-30
项目状态：
未结题

项目摘要

This proposal builds upon our metabolomics expertise in untargeted and targeted metabolomics for the generation of highly sensitive and quantitative targeted multiplex assays. The idea behind generating such assays for radiation assessment and radiation injury in easily accessible biofluids (urine, blood, saliva) is to rapidly determine the extent of exposure of an individual and distinguish between the worried well and the exposed individuals that may require medical intervention. Highly quantitative approaches will be undertaken through liquid chromatography tandem mass spectrometry (LC-MS/MS) to quantify each already identified radiation biomarkers in each biofluid. Such instruments are currently used routinely in clinical laboratories, therefore maximizing the available resources for rapid evaluation of thousands of individuals during an emergency. Based on criteria for sensitivity, high signal-to-noise ratio, low signal suppression from matrix effects, and high fold changes compared to controls or relationships between pairs of metabolites, biosignatures will be assembled and concentrations calculated. The combined biosignature will be developed in a multiplex assay, effectively reducing the time between sample preparation to results. The goal is to demonstrate that this multiplex assay method has the potential to be deployed in the case of an emergency to a pre-determined network of clinical laboratories that can accept and rapidly process a high volume of samples. While the ultimate goal will be for such a panel to be predictive in all cases, even a limited false positive rate would facilitate assessment of radiation injury in a mass casualty scenario: e.g. a 1% false positive rate would reduce the number of individuals needing further evaluation by 100-fold. Additionally, this assay will be flexible as it could be enriched with biomarkers for specificity and radiation quality. This application also combines the engineering experience and capabilities of our collaborators to further develop pre-processing devices with the intention of stabilizing the sample during transport to a clinical facility. The materials to be fabricated will also aim to enrich the biosignature for the radiation-related metabolites and extract them effectively from small amounts of a biofluid (urine, serum, whole blood, saliva), transported as a stable dry membrane. Assembly of such materials in a 96 well plate will further decrease the sample preparation time and minimize human error associated with sample preparation. Our unique approach to combine LC-MS/MS applications with pre-processing materials will aim to move this technology from the feasibility stage to technology development, satisfying the needs for rapid methods for radiation injury assessment.

这项建议建立在我们在非靶向和靶向代谢组学方面的专业知识基础上产生高灵敏度和定量的靶向多重分析。产生这样一个概念背后的想法在容易获得的生物体液(尿液、血液、唾液)中进行辐射评估和辐射损伤检测的方法是迅速确定个人接触的程度，并区分担心的健康和可能需要医疗干预的接触者。将采取高度量化的方法通过液-质联用(LC-MS/MS)对已鉴定的每一个每种生物流体中的辐射生物标记物。这种仪器目前在临床实验室中被常规使用，因此，最大限度地利用可用资源，在紧急情况。基于灵敏度、高信噪比、矩阵低信号抑制标准作用，以及与对照或代谢产物对之间的关系相比的高倍数变化，将收集生物签名并计算浓度。将开发组合的生物签名在多重分析中，有效地减少了从样品准备到结果的时间。我们的目标是证明这种多重分析方法具有在紧急情况下部署的潜力预先确定的临床实验室网络，可以接受并快速处理大量样本。虽然最终目标将是让这样一个小组在所有情况下都具有预测性，即使是有限的错误在大规模伤亡的情况下，阳性率将有助于评估辐射损伤：例如，错误1% 阳性率将使需要进一步评估的人数减少100倍。此外，这一点检测将是灵活的，因为它可以用特异性和辐射质量的生物标记物来丰富。这应用程序还结合了我们协作者的工程经验和能力，以进一步开发前处理设备，目的是在将样品运送到临床设施期间稳定样品。这个将制造的材料还将致力于丰富与辐射相关的代谢物的生物特征，并从少量的生物液体(尿液、血清、全血、唾液)中有效地提取它们，作为稳定的干膜。将这种材料组装在96孔板中将进一步减少样品缩短了样品制备时间，最大限度地减少了样品制备过程中的人为错误。我们独特的方法来处理将LC-MS/MS应用与前处理材料相结合，旨在将这项技术从技术开发进入可行性阶段，满足辐射损伤快速检测方法的需求评估。